Barclays’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Barclays’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-282,303	Closed	-$9.87M	–	5455
2024 Q1	$9.87M	Buy	282,303 +193,438	+218%	+$7.05M	﹤0.01%	1396
2023 Q4	$3.1M	Buy	88,865 +25,688	+41%	+$550K	﹤0.01%	2534
2023 Q3	$1.15M	Sell	63,177 -5,357	-8%	-$112K	﹤0.01%	2230
2023 Q2	$1.76M	Buy	68,534 +3,873	+6%	+$90.5K	﹤0.01%	1964
2023 Q1	$1.19M	Sell	64,661 -41,942	-39%	-$975K	﹤0.01%	2600
2022 Q4	$2.56M	Buy	106,603 +19,525	+22%	+$574K	﹤0.01%	2084
2022 Q3	$1.52M	Buy	87,078 +83,981	+2,712%	+$1.51M	﹤0.01%	1922
2022 Q2	$38K	Sell	3,097 -1,481	-32%	-$21.8K	﹤0.01%	4152
2022 Q1	$102K	Buy	+4,578	New	+$117K	﹤0.01%	3774

Other funds holding INBX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Barclays's INBX Position: Q2 2024 in Review

Barclays sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 282,303 shares — an estimated $9.87M sold.

Barclays first reported a position in INBX in Q1 2022 and held it in 9 quarters. The position peaked at $9.87M in Q1 2024. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

Barclays reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Barclays sold 282,303 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $9.87M.
Barclays first reported a position in Inhibrx, Inc. Common Stock in Q1 2022 and held it in 9 quarters.
Barclays's Inhibrx, Inc. Common Stock position peaked at $9.87M in Q1 2024.
2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on Barclays's 13F filing for Q2 2024, filed 14 Aug 2024.